ClinicalTrials.Veeva

Menu

Hydroxychloroquine in COVID-19 Patients

S

Samah Lutfy

Status and phase

Unknown
Phase 2

Conditions

COVID-19

Treatments

Drug: Hydroxychloroquine

Study type

Interventional

Funder types

Other

Identifiers

NCT04394442
SNH1352020

Details and patient eligibility

About

Many reports argued about the possible beneficial effects of Hydroxychloroquine in treating COVID-19 patients and this study was designed to investigate this claim

Enrollment

200 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Confirmed cases of SARS-CoV-2 by PCR

Exclusion criteria

less than 18 years old known hypersensitivity to the drug

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

200 participants in 2 patient groups

Hydroxycholoroquine group
Experimental group
Treatment:
Drug: Hydroxychloroquine
Control group
No Intervention group

Trial contacts and locations

1

Loading...

Central trial contact

Samah M Lutfy, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems